Summary

James recalls a concert in Juan-les-Pins in Antibes, France where he saw one of the best performances he can remember (swanky locale under the pines). And a tip of the hat to the Wedding Present whose gigs he says were "always amazing"

In this episode of Melanoma Matters, James and Sapna discuss the long-term follow-up results of the COMBI-AD study, which evaluates the efficacy of adjuvant therapy in melanoma patients with BRAF mutations. They delve into the statistical significance of the results, discuss the V600K subset, and explore the implications of subsequent therapies on overall survival. The conversation emphasizes the importance of patient-centric approaches in treatment decisions and the need for ongoing research in the field of melanoma.

Keywords

COMBI-AD, dabrafenib, trametinib, melanoma, adjuvant therapy, V600E, V600K, overall survival, RFS, targeted therapy, immunotherapy, long-term follow-up

Takeaways

• The COMBI-AD study represents the longest follow-up in an adjuvant trial.
• Statistical significance in overall survival is crucial for interpreting results.
• V600K patients show an RFS benefit but lack OS benefit.
• Subsequent therapies can impact overall survival outcomes.
• Adjuvant treatment aims to prevent relapse in melanoma patients.
• Patient-centric approaches are essential in treatment discussions.
• Long-term data provides confidence in treatment recommendations.
• The curves for RFS are starting to plateau over time.
• Understanding the natural history of V600K is still a challenge.
• Ongoing research is needed to better understand treatment outcomes.

Titles

COMBI-AD: A Decade of Data

Sound Bites

"This is the longest follow-up we've ever seen."

"The OS has a P value of 0.0000-something."

"V600K patients have an RFS benefit."

Chapters

00:00 Best Concert

04:32 Overview of the COMBI-AD Trial

07:09 Analysis of Overall Survival and Subgroups

10:54 Subsequent Therapies in the COMBI-AD Trial

17:09 Exploratory Analysis of Subgroups by Subsequent Therapy

19:56 Considerations for V600K Patients in the Adjuvant Setting

22:58 The Role of Adjuvant Therapy and Individualized Treatment Decisions

25:37 Long-term Follow-up Data and Counseling Patients